药师领导的SABA过度使用筛查结合FeNO管理高风险哮喘患者:一项试点研究
Pharmacist-led SABA overuse case-finding combined with FeNO supported management of high-risk symptomatic patients with asthma: a pilot study
一项在荷兰两家社区药房进行的试点研究显示,通过药师领导的SABA过度使用筛查结合FeNO检测,可有效识别高风险哮喘患者,并在3和6个月随访中显著降低FeNO和哮喘控制问卷评分(p < 0.05)。
Introduction
High short-acting beta agonists (SABA) use is associated with uncontrolled asthma. Fractional exhaled nitric oxide (FeNO) indicates airway inflammation using an easy to administer point-of-care test. Both are easy to measure in primary care. As such, using FeNO, high SABA users with clinical need for initiating inhaled corticosteroids (ICS), increasing ICS dose or enhancing ICS adherence can be proactively identified.
Aim
To explore the value of FeNO supported interventions in high-risk symptomatic asthma patients selected by pharmacists.
Methods
Multi-center, single arm, pre-post intervention pilot study in two Dutch community pharmacies, led by respiratory pharmacists, in collaboration with primary care colleagues. Asthma patients aged 18–40 years and SABA overuse and/or oral steroid courses were invited for FeNO measurement, and the Asthma Control Questionnaire (ACQ) and Test of Adherence to Inhalers (TAI) were administered. This prompted tailormade interventions (inhaler technique/adherence feedback, (re)start/increase ICS dose, asthma self-management plan, stop smoking advice and/or referral to general practitioner [GP]). Follow-up was at 3 and 6 months. FeNO and ACQ differences between baseline and 6 months were compared using 2-sided paired samples T-tests.
Results
In total, 34 patients (mean age: 28.5 years; 52.9% male; 14.7% smoker) were included and completed 6 months follow-up. At baseline, 20.6% used no ICS, 14.7% used ICS on-demand and up to 16 SABA devices per patient were dispensed. Mean baseline FeNO was 39.9 (SD: 34.7) ppb, mean ACQ 1.23 (SD: 1.05) and mean TAI-10: 45.0 (SD: 5.7). At 6-months follow-up, mean FeNO and ACQ decreased significantly (both p < 0.05) to 26.5 ppb and 0.74, respectively.
Conclusion
By providing high-risk symptomatic asthma patients with FeNO supported interventions, both inflammation and asthma control could be reduced.
来源:Nature 健康护理主题 · nature.com